Bayer Debuts Industry-First PET Blister Packaging for Aleve, Pioneering Sustainable Change in Healthcare Packaging

Bayer has launched a first-of-its-kind in the healthcare industry, polyethylene terephthalate (PET) blister packaging on its renowned brand, Aleve. Reali...

October 31, 2024 | Thursday | News
Oxford Medical Products Announces Promising Topline Results from First RCT of Sirona Weight Loss Technology

 Oxford Medical Products is pleased to announce positive topline results from the first randomised controlled trial (RCT) of Sirona, its innova...

October 31, 2024 | Thursday | News
Ardena Expands Bioanalytical Services with New Lab in Oss, Netherlands, Enhancing Capabilities to Meet Growing Client Demand

  Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...

October 31, 2024 | Thursday | News
GSK Acquires CMG1A46 from Chimagen for $300 Million to Target B Cell-Driven Autoimmune Diseases

GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...

October 30, 2024 | Wednesday | News
MSD and Moderna Launch Pivotal Phase 3 Trial for V940 in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the initiation of INTerpath-009, a piv...

October 29, 2024 | Tuesday | News
AstraZeneca’s Fasenra Receives EU Approval as Add-On Treatment for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...

October 29, 2024 | Tuesday | News
Orexo Begins Dosing for Intranasal Epinephrine Study in Allergy Patients, Aiming to Advance OX640 Toward Regulatory Approval

OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...

October 28, 2024 | Monday | News
Novartis Unveils Promising 12-Month Data for Fabhalta® in C3 Glomerulopathy at ASN Kidney Week 2024

Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...

October 28, 2024 | Monday | News
Regeneron and Sanofi Present Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...

October 25, 2024 | Friday | News
AbbVie and Gedeon Richter Forge New Agreement to Explore Treatments for Neuropsychiatric Disorders

 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...

October 25, 2024 | Friday | News
GSK Announces Promising Data for Arexvy Vaccine in Younger Adults at Risk for RSV

GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...

October 25, 2024 | Friday | News
European Commission Approves KEYTRUDA for New Indications in Gynecologic Cancers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for K...

October 25, 2024 | Friday | News
PolTREG’s Early Treatment with PTG-007 Could Offer Functional Cure for Children at Risk of Type 1 Diabetes

Treating diabetes patients earlier with PTG-007 could provide functional cure Recruitment will go ahead after European Medicines Agency approval Comp...

October 24, 2024 | Thursday | News
Eli Lilly’s Donanemab Receives MHRA Approval for Alzheimer's Treatment in Great Britain

Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...

October 24, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close